Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13808849 | 1.00 | ABHD6 (0.41) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL13705180 | 0.99 | ABHD6 (0.42) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL13705188 | 0.98 | ABHD6 (0.42) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL13808855 | 0.96 | ABHD6 (0.42) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL13705193 | 0.96 | ABHD6 (0.42) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL13705187 | 0.95 | ABHD6 (0.43) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL13705186 | 0.92 | ABHD6 (0.43) | ABHD6DAGLAHDAC1PARP1DPP4 | |
| SCHEMBL4281688 | 0.92 | CA1 (0.35) | — | |
| SCHEMBL4281682 | 0.92 | CA1 (0.35) | — | |
| SCHEMBL4281686 | 0.92 | CA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ABHD6 3736/4885DAGLA 4309/4885HDAC1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.